Pyramid Biosciences and Caris Life Sciences have entered a partnership to boost potential participant identification with NTRK fusion-driven cancers for the ongoing Phase I/II PBI-200-101 clinical trial of the former’s PBI-200.
A lead oncology programme of Pyramid, PBI-200 is a CNS-penetrant TRK inhibitor.
The multicentre, open-label, international Phase I/II trial will enrol NTRK fusion-positive advanced or metastatic tumour patients, including those with primary and metastatic CNS tumours.
It will have a dose-escalation phase and a subsequent multicohort expansion at the recommended Phase II dose of PBI-200.
Pyramid Bio CEO Brian Lestini said: “This collaboration will further advance the promise of precision oncology, with the potential to deliver highly differentiated compounds against validated cancer targets.
“Caris’ patient identification and matching service is invaluable for enabling the development of novel precision therapies, especially in genetically-defined populations like NTRK.”
In preclinical studies, PBI-200 demonstrated to attain increased levels of penetration into the brain, which translated to improved efficacy in intracranial xenograft models versus other TRK inhibitors.
It was also found to possess a favourable safety profile.
Caris focuses on the development and delivery of new solutions to transform healthcare. The customised Molecular Intelligence Trials (MI Trials) of the company aid in matching the right participants to the right trials.
The matching is made based on the molecular tumour profile of the patient and the trial’s eligibility needs.
Caris provides a growing portfolio of trials through its Right-In-Time clinical trial solution, with more than 50 therapy options available.
Furthermore, over 450 research-ready trial centres are available if a patient is detected using a Caris molecular profile outside a current sponsor study site.
This network aids in offering trials to patients who are otherwise unable to gain access to such new treatments.